Physician profile

Apurva Vedire

Neptune, NJ

NPI 1336721026

$689.67

in general payments reported to CMS, 2019-2025

7 companies · $393 in 2025

The $393 reported for 2025 was more than what 75% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$596.68
Education$92.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Gilead Sciences, INC. $143.50 2025 Trodelvy
Astrazeneca Pharmaceuticals LP $125.00 2025
Pharmacosmos Therapeutics INC. $124.97 2025 Cosela
Intera Oncology, INC $115.02 2024 Intera
Genmab U.S., INC. $110.18 2024 Epkinly
Abbvie INC. $50.71 2024
Genzyme Corporation $20.29 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Apurva Vedire

$689.67

in general payments reported 2019-2025

Years
2024-2025
Top company
Gilead Sciences, INC.
Context
The $393 reported for 2025 was more than what 75% of providers received nationally.

https://glasscript.com/doctor/11684430/apurva-vedire

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.